Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Iris adds body fluid module to urinalysis analyser:

This article was originally published in Clinica

Executive Summary

Expanding the US market for its iQ200 automated urinalysis analyser, Iris International has gained FDA 510(k) clearance to add to the product a body fluids module for analysing cerebrospinal and serous body fluid. "This is the first in a series of planned extensions of our proprietary urinalysis technology with iQ200 product add-ons targeting the analysis of critical body fluids other than urine," said the Chatsworth, California firm's president and CEO Cesar Garcia. Increasing iQ200's capabilities is expected to enable sales of the analyser platform and related consumables to additional hospitals. It would also allow hospitals with a lower volume of urinalysis tests to justify an iQ200 purchase. Since its launch in August 2003, over 400 iQ200 analysers have been shipped to Iris' customers and distributors worldwide.

You may also be interested in...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts